Holen Sie sich die Stockscreener-App
3.67
6.62%
-0.26
Handel nachbörslich:
3.67
Schlusskurs vom Vortag:
$3.93
Offen:
$4.0917
24-Stunden-Volumen:
43,678
Relative Volume:
0.95
Marktkapitalisierung:
$117.66M
Einnahmen:
$15.33M
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-18.08%
1M Leistung:
-12.41%
6M Leistung:
-62.74%
1J Leistung:
-3.93%
1-Tages-Spanne:
$3.61
$4.0917
1-Wochen-Bereich:
$3.61
$4.655
52-Wochen-Spanne:
$3.32
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Firmenname
Trisalus Life Sciences Inc
Sektor
Branche
Telefon
415 336 8917
Adresse
6272 WEST 91ST AVENUE, WESTMINSTER
Vergleichen Sie TLSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TLSI | 3.67 | 117.66M | 15.33M | -40.19M | 0 | 0.00 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - MarketBeat
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Q3 Earnings Estimate for TLSI Issued By Roth Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Roth Capital to "Strong-Buy" Rating - MarketBeat
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target By Investing.com - Investing.com South Africa
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target - Investing.com Canada
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Roth Mkm - MarketBeat
Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav - Business Wire
Reviewing TriSalus Life Sciences (TLSI) and Its Peers - Defense World
Critical Comparison: CARGO Therapeutics (CRGX) and Its Rivals - Defense World
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment - BioSpace
TriSalus Life Sciences (TLSI) to Release Quarterly Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on Thursday - Defense World
TriSalus Life Sciences® Inc. Launches TriNav® LV Infusion System and TriGuide? Guiding Catheters, Expanding Portfolio of PEDD? Devices for Improved Tumor Treatment - Marketscreener.com
TriSalus Life Sciences, Inc. Announces Resignation and Departure of Board Member and Chief Medical Officer - Defense World
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call - BioSpace
Northland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA - openPR
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in October - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Northland Capmk Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy" - MarketBeat
Northland initiates TriSalus shares with outperform, cites sales growth - Investing.com India
Northland initiates TriSalus shares with outperform, cites sales growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Northland Securities - MarketBeat
ALUS presents the 2024 Dave Reid Award to François Allard - GlobeNewswire Inc.
Riad Salem Joins Scientific Advisory Board Of TriSalus Life Sciences - MPO-mag
Riad Salem Joins Scientific Advisory Board of TriSalus Life Sciences - MPO-mag
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - BioSpace
Interventional Approaches for Locally Advanced Pancreatic Cancer - HMP Global Learning Network
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in September - MarketBeat
Bluefin Capital Management LLC Purchases New Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) - Defense World
TriSalus Life Sciences, Inc. Announces Appointment of Riad Salem to its Scientific Advisory Board - Marketscreener.com
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board - BioSpace
TriSalus Life Sciences adds oncology expert to SAB By Investing.com - Investing.com South Africa
TriSalus Life Sciences adds oncology expert to SAB - Investing.com India
Magnetar Financial LLC Has $1.05 Million Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) - Defense World
Public Sector Pension Investment Board Has $6.40 Million Stake in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Terrain Minerals Welcomes New Major Investor - TipRanks
TrivarX Boosts Board with Healthcare Expertise - TipRanks
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com UK
Progeny 3 Inc. Raises Stock Holdings in Sixth Street Specialty Lending, Inc. (NYSE:TSLX) - Defense World
940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLC - Defense World
Telesis Bio Inc (TBIO) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Finanzdaten der Trisalus Life Sciences Inc-Aktie (TLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):